Kanishk Mehta¹*, Priti Agarwal² and Swati Jain³

¹Associate Professor, Department of Otorhinolaryngology and Head Neck Surgery, American International Institute of Medical Sciences, Udaipur, Rajasthan, India
²Professor and Head, Department of Pathology, American International Institute of Medical Sciences, Udaipur, Rajasthan, India
³Assistant Professor, Department of Ophthalmology, American International Institute of Medical Sciences, Udaipur, Rajasthan, India

*Corresponding Author: Kanishk Mehta, Associate Professor, Department of Otorhinolaryngology and Head Neck Surgery, American International Institute of Medical Sciences, Udaipur, Rajasthan, India.

Received: May 24, 2021; Published: June 10, 2021

Abstract

Patients with Coronavirus disease (COVID-19) are commonly treated with broad spectrum antibiotics, glucocorticoids and/or immune modulators. This has led to development/exacerbation of opportunistic fungal infections. Mucormycosis is one such disease that complicates the course of severe COVID-19. Here we present a study of 15 patients and their epidemiology who were diagnosed with Covid19 Associated Mucormycosis (CAM) at our institute - the highest number of cases in literature.

Keywords: Mucormycosis; COVID19; Immunosuppression

References

1. Mehta S and Pandey A. “Rhino-Orbital Mucormycosis Associated with COVID 19”. Cureus9 (2020): e10726.
2. Chen N., et al. “Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study”. Lancet 395 (2020): 507-513.
3. Rawson TM., et al. “Bacterial and fungal co-infection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing”. Clinical Infectious Diseases (2020).
4. Clinical management protocol for COVID-19 (2020).
5. RECOVERY Collaborative Group; Peter Horby., et al. “Dexamethasone in hospitalized patients with Covid-19 - preliminary report. The RECOVERY Collaborative Group”. The New England Journal of Medicine (2020).
6. COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health (2020).
7. Gangneux JP., et al. “Invasive fungal diseases during COVID-19: we should be prepared”. Journal of Medical Mycology 30 (2020): 100971.
8. Singh A., et al. “Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India” (2021).
9. AM Sugar. “Mucormycosis”. Clinical Infectious Disease 14 (1992): S126-S129.

Citation

Citation: Kanishk Mehta., et al. “Covid 19 Associated Mucormycosis: An Epidemic".Acta Scientific Otolaryngology 3.7 (2020): 27-31.

Copyright

Copyright: © 2020 Kanishk Mehta., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.